Estrogen Receptor-negative Breast Cancer Completed Phase 2 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0028543 (Estrogen Receptor-negative Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00194779Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By SurgeryTreatment